title: Oncolytic virotherapy of breast cancer.
abstract: The use of replication competent viruses that selectively target and destroy cancer cells has rapidly evolved over the past decade and numerous innovative oncolytic viruses have been created. Many of these promising anti-cancer agents have recently entered into clinical trials (including those on breast cancer) and demonstrated encouraging safety and efficacy. Virotherapeutic strategies are thus of considerable interest to combat breast cancer in both (i) the primary disease situation in which relapse should be avoided as good as possible and (ii) in the metastatic situation which remains incurable to date. Here, we summarize data from preclinical and clinical trials using oncolytic virotherapy to treat breast cancer. This includes strategies to specifically target breast cancer cells, to arm oncolytic viruses with additional therapeutic transgenes and an outlining of future challenges when translating these promising therapeutics "from bench to bedside".
authors.affiliation: Department of Obstetrics and Gynecology, University Clinic of Tuebingen, Tuebingen, Germany. andreas.hartkopf@med.uni-tuebingen.de
authors.forename: Andreas D
authors.initials: AD
authors.lastname: Hartkopf
authors.forename: Tanja
authors.initials: T
authors.lastname: Fehm
authors.forename: Diethelm
authors.initials: D
authors.lastname: Wallwiener
authors.forename: Ulrich M
authors.initials: UM
authors.lastname: Lauer
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000628:therapy* / Q000821:virology*; D005260:Female; D006801:Humans; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000502:physiology*